Chemomab Therapeutics (CMMB) Other Operating Expenses (2019 - 2020)

Chemomab Therapeutics (CMMB) posted Other Operating Expenses of $5.1 million for Q4 2020, up 6588.61% on a QoQ basis from -$79000.0 in Q3 2020, and up 53.01% year-over-year from $3.4 million in Q1 2020.

Chemomab Therapeutics (CMMB) Other Operating Expenses (2019 - 2020) Analysis & Trends

Chemomab Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $5.1 million for Q4 2020.

  • Quarterly Other Operating Expenses rose 53.01% year-over-year to $5.1 million in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $5.1 million (up 97.08% YoY) and the FY2021 annual result came in at -$216000.0, down 104.93% from the prior year.
  • Other Operating Expenses was $5.1 million for Q4 2020 at Chemomab Therapeutics, up from -$79000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.1 million in Q4 2020 and bottomed at -$670000.0 in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Chemomab Therapeutics 124.14 Mn 113.77 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 5.13 Mn
Sep 30, 2020 -79,000.00
Mar 31, 2020 -670,000.00
Dec 31, 2019 3.35 Mn